M2K Bio designs and deploys
local Databricks-style Lakehouse AI architectures that unify data engineering, analytics, and machine learning into a single, high-performance platform—without the cost, vendor lock-in, or data-exposure risks of managed cloud services. These open, scalable systems give organizations full control over sensitive data while enabling reproducible AI workflows, enterprise-grade governance, and seamless integration with on-prem and HPC infrastructure.
M2K (Aptis) Bio leverages advanced artificial intelligence, generative deep learning, and structural biophysics to advance next-generation therapeutic biologics discovery. Combining computational protein design with structure-guided engineering, we develop high-affinity, de novo miniproteins, VHH nanobodies, paired Fv domains, and cyclic peptides precisely tailored to target epitope hotspots. Our integrated AI-driven discovery platform accelerates the design and optimization of therapeutic binders, prioritizing binding affinity, structural stability, manufacturability, and favorable developability profiles while addressing potential immunogenicity liabilities. By bridging computational innovation and molecular engineering, M2K (Aptis) Bio aims to transform biologics discovery and enable the development of precision therapeutics across oncology, immunology, and infectious diseases.
Partner with us to explore the potential of AI-driven biologics design. Request a custom design study at
https://www.aptisbio.com/.
In summary, M2K Bio helps organizations: design and deploy local Lakehouse AI architectures; design and optimize antibodies for targeted therapies; and analyze diverse omics data to drive faster, more effective biomedical innovation.